Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: caly who wrote (960)	9/5/1999 3:36:00 PM
From: JEB	Read Replies (1) \| Respond to of 2515

(April 14,1999) "These data in pancreatic cancer models provide further evidence that C225 as a single therapy or in combination with standard therapies can inhibit the growth and spread of a wide variety of cancer cells, including pancreatic cancer cells," stated Samuel D. Waksal, President and CEO of ImClone Systems. "What we have learned from these preclinical studies in a very difficult cancer model is now going to allow us to move forward in clinical trials for pancreatic carcinoma this quarter." We should be hearing about these clinical trials very soon, ...or has the street already picked up on this. ;-) JEB